All Stories

  1. Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era
  2. Characteristics of Adults With Addictions and Mental Health Problems Who Have Experienced Homelessness: A Population-Based Study From Alberta, Canada: Caractéristiques des adultes aux prises avec des problèmes de dépendance et de santé mentale et ayant...
  3. Integrated Management of Co-Occurring Alcohol Use Disorder and Depression: Clinical Approaches for Concurrent Disorders
  4. Emerging pharmacological strategies for the treatment of cannabis use disorder
  5. The Unseen Addiction: Improving Surveillance and Governance of Medical Cannabis in Canada
  6. Limitations and Future Directions in Pharmacological Treatment for Amphetamine-Type Stimulant Use Disorder
  7. What Psychiatrists Should Know About Prescribed Safer Opioid Supply
  8. Postdischarge Mortality in a Cohort Hospitalized With Anorexia Nervosa
  9. Impact of Depressive Symptom Severity on Buprenorphine/Naloxone and Methadone Outcomes in People With Prescription-Type Opioid Use Disorder: Results From a Pragmatic Randomized Controlled Trial
  10. Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review
  11. Associations between Gender Expression, Protective Coping Strategies, Alcohol Saliency, and High-Risk Alcohol Use in Post-Secondary Students at Two Canadian Universities
  12. Associations between Gender Expression, Protective Coping Strategies, Alcohol Saliency, and High-Risk Alcohol Use in Post-Secondary Students at Two Canadian Universities
  13. Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis
  14. Evidence base to support using prescribed psychostimulants to treat psychostimulant use disorder is limited
  15. Navigating Evidence, Challenges, and Caution in the Treatment of Stimulant Use Disorders
  16. Implications of Cannabis Legalization on Substance-Related Benefits and Harms for People Who Use Opioids: A Canadian Perspective
  17. Cannabis use disorder and adverse cardiovascular outcomes: A population‐based retrospective cohort analysis of adults from Alberta, Canada
  18. The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
  19. Ketamine for the treatment of major depression: a systematic review and meta-analysis
  20. Ways to get a more balanced gender representation in addiction journals’ management and workforce
  21. Cases: Multiorgan failure in a 38-year-old man with recent consumption of kratom, an atypical opioid
  22. The Effectiveness of Inpatient Addiction Consult Services: A Systematic Review and Narrative Synthesis
  23. Guilty until proven innocent
  24. Assessing research competency development in Canadian psychiatry residency programs: A systematic review and future directions
  25. Association Between Substance Use and Professional Outcomes Among Medical Students: Findings from a Canadian Cross-sectional Survey
  26. Managing Comorbid Tobacco Use Disorder for Individuals With Schizophrenia: Challenges and Opportunities
  27. Letter to the Editor: Cannabis as a Solution to the Opioid Crisis: Is the Cart Before the Horse Again?
  28. Psychological interventions for post-traumatic stress injuries among public safety personnel: a systematic review and meta-analysis
  29. Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis
  30. The Rising Tide of Stimulant-Related Morbidity and Mortality Warrants Evidence-Based Treatment
  31. The critical role of peer reviewers: Challenges and future steps
  32. Factors Associated With Past-year and Lifetime Prevalence of Cannabis Withdrawal: A Secondary Analysis
  33. Trends in Canadian Cannabis Consumption Over Time: A Two-step Meta-analysis of Canadian Household Survey Data
  34. Prevalence and factors associated with polypharmacy: a systematic review and meta-analysis
  35. Management of Post-Acute Alcohol Withdrawal: A Mixed-Studies Scoping Review
  36. Neurobiology and Symptomatology of Post-Acute Alcohol Withdrawal: A Mixed-Studies Systematic Review
  37. Exclusion of the non-English-speaking world from the scientific literature: Recommendations for change for addiction journals and publishers
  38. Challenges and opportunities for further research involving the cannabis‐to‐opioid use transition
  39. Self-Reported Cannabis Use and HIV Viral Control among Patients with HIV Engaged in Care: Results from a National Cohort Study
  40. Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: a systematic review and network meta‐analysis
  41. Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review
  42. Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis
  43. Comment on “I’m Virtually a Psychiatrist: Problems with Telepsychiatry in Training”
  44. Patients With Infective Endocarditis Deserve Evidence-based Addiction Treatment
  45. Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders
  46. The Prevalence of Impulse Control Disorders and Behavioral Addictions in Eating Disorders: A Systematic Review and Meta-Analysis
  47. Considering Cannabis Use in Differential Diagnosis
  48. Listening to the Patient's Voice: A Patient-Centred Approach to Treatment-Resistant Schizophrenia
  49. The prevalence of substance use disorders and substance use in anorexia nervosa: a systematic review and meta-analysis
  50. Prevalence of and Factors Associated With Substance Use Among Canadian Medical Students
  51. What are the clinical implications of Bahá’í perspectives of psychiatry and mental health?
  52. Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis
  53. Genetic markers of the stress generation model: A systematic review
  54. Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis
  55. Concurrent Disorders Management in Psychiatric Care: Opportunities and Challenges
  56. The Prevalence of Cannabis Use Disorder Comorbidity in Individuals With Bipolar Disorder: A Systematic Review and Meta-Analysis
  57. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium
  58. Supporting Persons Who Use Drugs During the COVID-19 Pandemic: A Rapid Review of International Guidelines
  59. Towards competency-based medical education in addictions psychiatry: a systematic review
  60. Ketamine for Bipolar Depression: A Systematic Review
  61. Proactive psychological programs designed to mitigate posttraumatic stress injuries among at-risk workers: a systematic review and meta-analysis
  62. Comparative Efficacy and Acceptability of Psychotherapies for Self-harm and Suicidal Behavior Among Children and Adolescents
  63. Making a case for the inclusion of refractory and severe mental illness as a sole criterion for Canadians requesting medical assistance in dying (MAiD): a review
  64. Misuse and dependence of dimenhydrinate: A mixed studies systematic review
  65. Transcranial direct current stimulation for empathy: A systematic review and meta-analysis
  66. Psychological interventions for posttraumatic stress injuries among public safety personnel: a systematic review and meta-analysis
  67. Coping among public safety personnel: A systematic review and meta–analysis
  68. Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?
  69. Policy Brief: CSAM in Support of the Decriminalization of Drug Use and Possession for Personal Use
  70. Recent Advances in Biomarkers of Addiction: A Narrative Review
  71. Erratum to “Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis” [Journal of Affective Disorders 278C (2021) 542–555]
  72. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
  73. Response to Canadian Psychiatric Association Cannabinoid Products Position Statement: Potential for Ameliorating Cannabis Withdrawal
  74. Alcohol-Related Psychiatric Presentations at a University-Affiliated Emergency Department: A Descriptive Prevalence Study
  75. Comparative Efficacy and Tolerability of Adjunctive Pharmacotherapies for Acute Bipolar Depression: A Systematic Review and Network Meta-analysis
  76. COVID-19 and the Need for Leadership Training in Psychiatry
  77. The Substance Treatment and Recovery Team (START): Measuring the effectiveness and feasibility of an inpatient addiction consult service at an academic general hospital
  78. Efficacy and acceptability of cannabinoids for anxiety disorders in adults: A systematic review & meta-analysis
  79. The Addictive Nature of Compulsive Sexual Behaviours and Problematic Online Pornography Consumption: A Review
  80. Response to Canadian Psychiatric Association Opioid Use Disorder Position Statement: More than Just Collaborators in Care
  81. The Impact of Community Treatment Orders on Substitute Decision Makers
  82. Predictors of hospital admission for patients presenting with psychiatric emergencies: A retrospective, cohort study
  83. Virtual psychiatric care for older adults in the age of COVID‐19: Challenges and opportunities
  84. How to Serve the Underserved: Making the Case for Rural and Remote Mental Health Training for Psychiatry Residents
  85. Harm Reduction for Injection Drug Users with Infective Endocarditis: A Systematic Review
  86. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis
  87. Effectiveness of Pharmacotherapies for Bipolar Depression: A Systematic Review & Network Meta-Analysis
  88. Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids
  89. Incidence and Correlates of Cannabinoid-Related Psychiatric Emergency Care: A Retrospective, Multiyear Cohort Study
  90. Methamphetamine-Related Emergency Department Visits Requiring Psychiatric Admission: A Retrospective Cohort Study
  91. Mortality Among People With Opioid Use Disorder: A Systematic Review and Meta-analysis
  92. Commentary on Hayes et al. (2020): The harms of opioid dose escalation in the management of chronic non‐cancer pain
  93. Acknowledgement to Reviewers of JCM in 2019
  94. Acceptability and efficacy of naltrexone for criminal justice‐involved individuals with opioid use disorder: a systematic review and meta‐analysis
  95. Systematic Review and Meta-Analyses of Psychotherapies for Adolescents with Subclinical and Borderline Personality Disorder: A Reply to the Commentary by Jørgensen, Storebø, and Simonsen
  96. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis
  97. Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis
  98. Prevalence of intimidation, harassment, and discrimination in resident physicians: a systematic review and meta-analysis
  99. At-a-glance - The local response to the Canadian opioid epidemic in the Kingston, Frontenac, and Lennox and Addington communities
  100. 2.62 PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADOLESCENTS WITH SUBCLINICAL AND BORDERLINE PERSONALITY DISORDER: A SYSTEMATIC REVIEW AND META-ANALYSIS
  101. Psychotherapies for Adolescents with Subclinical and Borderline Personality Disorder: A Systematic Review and Meta-Analysis
  102. Reduction in mortality risk with opioid agonist therapy: a systematic review and meta‐analysis
  103. International Perspectives on the Implications of Cannabis Legalization: A Systematic Review & Thematic Analysis
  104. What are the key considerations for clinicians treating Bahá'í patients with psychiatric disorders?
  105. Commentary on Stockings et al . (2019): The global amphetamine epidemic — a rising tide of mortality
  106. The Value of Hospitalization in the Opioid Epidemic
  107. Is stigma preventing knowledge translation and utilization of electroconvulsive therapy for depression?
  108. Management of endocarditis among persons who inject drugs: A narrative review of surgical and psychiatric approaches and controversies
  109. Piloting an Addictions Medicine Consultation Team in Kingston, Ontario, Canada
  110. Prevalence of substance use disorder comorbidity among individuals with eating disorders: A systematic review and meta-analysis
  111. Characterizing inpatient care for adults with schizophrenia using the Health Quality Ontario indices: A single-centre retrospective cohort study
  112. A Critical Review of Addictions Curriculum in Canadian Residency Programs
  113. ECT beyond unipolar major depression: systematic review and meta‐analysis of electroconvulsive therapy in bipolar depression
  114. The Emerging Epidemic of Male Me-Too
  115. Attitudes to antipsychotics: a multi-site survey of Canadian psychiatry residents
  116. Assessing the utility of drug screening in the emergency: a short report
  117. Episodic Behavioural Regression in an 8-Year-Old Female: Sequelae of 22q11.2 Duplication Syndrome
  118. A case for opioid education and training for medical students, residents, and allied health staff: response to “educational intervention for physicians to address the risk of opioid abuse”
  119. Endocarditis in the setting of IDU
  120. Opioids on Trial
  121. Why residents need more training in prescribing antipsychotics for people with Schizophrenia
  122. Increasing awareness about HIV prevention among young people who initiated injection drug use in a Canadian setting, 1988–2014